TP53 and cancer: In p53 null cancers, inhibition of CX-5461 can activate Ataxia-telangiectasia-mutated (ATM) and ataxia telangiectasia and Rad3-related (ATR)-mediated signalling in the absence of global DNA damage leading to arrest in cell cycle progression [80,81].